| Sep 4 |
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 3 |
Psychedelic Stock Deep Dive: Atai Life Sciences
|
| Aug 23 |
Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report
|
| Aug 15 |
Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD
|
| Aug 13 |
Atai Life Sciences psychedelic drug for depression demonstrates safety in phase 1
|
| Aug 13 |
ATAI Life Sciences GAAP EPS of -$0.36, revenue of $0.27M
|
| Aug 13 |
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
|
| Aug 13 |
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
|
| Aug 12 |
Medical journal retracts three articles related to MDMA for PTSD
|
| Aug 9 |
Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA
|
